Alvio.Pa
ALVIO.PA operates in the pharmaceuticals industry, focusing on drug development and research, and generates revenue primarily through the sale of pharmaceutical products and services.
Business. ALVIO.PA operates in the pharmaceuticals industry, focusing on drug development and research, and generates revenue primarily through the sale of pharmaceutical products and services.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
ALVIO.PA operates in the pharmaceuticals industry, focusing on drug development and research, and generates revenue primarily through the sale of pharmaceutical products and services.
ALVIO.PA exhibits a highly leveraged capital structure, with total liabilities of EUR 26.86 billion and total equity of EUR -8.93 billion, resulting in a negative debt-to-equity ratio of -0.9. The company's liquidity position is weak, with a current ratio of 0.25 and cash and equivalents of EUR 1.18 billion, which is insufficient to cover its EUR 8.03 billion in long-term debt. The negative free cash flow of EUR -23.56 billion and operating cash flow of EUR -8.37 billion further indicate significant liquidity constraints.
Profitability metrics are severely negative, with a net loss of EUR -23.92 billion and an operating loss of EUR -23.73 billion. Return on equity is 2.68, but this is misleading due to the negative equity base. Return on assets is -1.33, indicating poor asset utilization. These figures fall well below the industry median for profitability and returns, suggesting underperformance relative to peers.
The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to market-specific risks and limits growth potential.
Growth trajectory is negative, with a reported revenue of EUR 1.79 billion. Analyst estimates suggest a slight increase to EUR 1.8 billion, but this is not indicative of meaningful growth. The company's operating and net losses suggest a challenging path to profitability.
Risk factors include high liquidity risk due to negative net cash and significant debt obligations. The company's dilution risk is currently low, but the negative equity position and high debt levels could necessitate future equity issuance, which would dilute existing shareholders. The risk assessment indicates a medium liquidity risk and a low dilution risk.
Recent events include a reported net loss and negative operating cash flow, which are consistent with the company's financial challenges. No recent filings or transcripts have been disclosed that provide additional insight into the company's strategic direction or financial health.
- ALVIO.PA is operating at a significant net loss with negative operating and free cash flows.
- The company's capital structure is highly leveraged, with a negative equity position and high debt levels.
- Profitability metrics are poor, with a negative return on assets and misleadingly high return on equity due to negative equity.
- The company lacks geographic and segment diversification, increasing its exposure to market-specific risks.
- Liquidity constraints are severe, with insufficient cash to cover long-term debt obligations.
- The company's growth trajectory is negative, with minimal revenue growth and significant losses.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- ALVIO.PA Market data — financials · 2026-05-27
- Valerio Therapeutics SA Market data — analyst estimates · 2026-05-27